Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.